Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of salvianolic acid A as drug for preventing and treating diabetic eye diseases

A technology of diabetic ophthalmopathy and salvianolic acid, applied in the field of medicine, can solve problems such as no reports on the effect of diabetic ophthalmopathy, and achieve the effects of improving retinal microvascular disease, improving macular edema, and reducing retinal thickness

Active Publication Date: 2017-11-10
CHIATAI QINGCHUNBAO PHARMA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its effect on diabetic eye disease has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of salvianolic acid A as drug for preventing and treating diabetic eye diseases
  • New application of salvianolic acid A as drug for preventing and treating diabetic eye diseases
  • New application of salvianolic acid A as drug for preventing and treating diabetic eye diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: Effect of intravenous injection of SAA on cataract in ZDF rats

[0023] Materials: SAA, normal saline (NS)

[0024] Experimental animals: SPF grade male ZDF rats and male ZL rats, both 7-8 weeks old.

[0025] 1. Experimental method

[0026] 1.1. Model establishment and group administration

[0027] Sixteen male ZDF rats aged 7-8 weeks were fed with Purina#5008 feed, and another 8 Zucker lean (ZL) rats of the same week were fed with basal feed. After 4 weeks, fasting without food and water for more than 12 hours, blood was taken from the tail vein, and the blood sugar level was measured. According to the blood sugar, the ZDF rats were divided into two groups, namely the model control group and the SAA group, with 8 rats in each group, and the ZL rats acted as normal control. group, a total of 3 groups. ZDF rats in SAA group were injected with SAA 1mg / kg by tail vein every day, and the model control group and normal control group were given 5mL / kg normal sa...

Embodiment 2

[0034] Example 2: Effect of intravenous injection of SAA on retinal microvascular lesions in ZDF rats

[0035] Materials: SAA, NS, sodium pentobarbital, formaldehyde fixative, trypsin, PAS staining kit, RBP detection kit, mALB detection kit

[0036] Experimental animals: SPF grade male ZDF rats and male ZL rats, both 7-8 weeks old.

[0037] 1. Experimental method

[0038] 1.1. Model establishment and group administration

[0039] Sixteen male ZDF rats aged 7-8 weeks were fed with Purina#5008 feed, and another 8 Zucker lean (ZL) rats of the same week were fed with basal feed. After 4 weeks, fasting without food and water for more than 12 hours, blood was taken from the tail vein, and the blood sugar level was measured. According to the blood sugar, the ZDF rats were divided into two groups, namely the model control group and the SAA group, with 8 rats in each group, and the ZL rats acted as normal control. group, a total of 3 groups. ZDF rats in SAA group were injected with...

Embodiment 3

[0051] Example 3: Effect of intravenous injection of SAA on macular edema in ZDF rats

[0052] Materials: SAA, NS, sodium pentobarbital, formaldehyde fixative, eosin stain, hematoxylin stain.

[0053] Experimental animals: SPF grade male ZDF rats and male ZL rats, both 7-8 weeks old.

[0054] 1. Experimental method

[0055] 1.1. Model establishment and group administration

[0056] Sixteen male ZDF rats aged 7-8 weeks were fed with Purina#5008 feed, and another 8 Zucker lean (ZL) rats of the same week were fed with basal feed. After 4 weeks, fasting without food and water for more than 12 hours, blood was taken from the tail vein, and the blood sugar level was measured. According to the blood sugar, the ZDF rats were divided into two groups, namely the model control group and the SAA group, with 8 rats in each group, and the ZL rats acted as normal control Group. ZDF rats in SAA group were injected with SAA 1mg / kg by tail vein every day, and the model control group and nor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses new application of salvianolic acid A (SAA) used in preparing drugs for preventing and treating diabetic eye diseases. A Zucker diabetic fat (ZDF) rats are induced through purina#5008 feed so as to build a diabetic model, and the intervention effect of the SAA on the diabetic eye diseases is observed. It is showed through research results that when the ZDF rats are continuously fed with the SAA for 12 weeks, the incidence rate of the ZDF rat cataract can be obviously reduced. Meanwhile, it is showed through pathology results that after the rats are fed with the SAA, the microvascular morphologies of the rat retinas are improved, and oedemata in the macular region are inhibited. Besides, it is showed through biochemistry results that when the rats are fed with the SAA, the serum transferrin level and the microalbuminuria excretion amount can be reduced, and the diabetic retinopathy is easy to prevent and treat. In a word, the SAA has the effect of improving the diabetic eye diseases, especially in the aspects of diabetic cataract, diabetic fundus arterial diseases and diabetic retina macular oedemata. The new application of the SAA is developed, and it is expected that the SAA can be used in preparation the drugs for preventing and treating the diabetic eye diseases.

Description

technical field [0001] The invention relates to the application of salvianolic acid A in preventing and treating diabetic eye disease, especially diabetic cataract, diabetic fundus arterial disease and diabetic retinal macular edema, and belongs to the technical field of medicine. Background technique [0002] Diabetes is a common endocrine and metabolic disease. Epidemiological surveys show that the number of patients has a tendency to increase rapidly in recent years. Diabetes has the characteristics of many complications, high morbidity and mortality, and its chronic complications mainly involve the lens, retina, kidney and peripheral nerves and other tissues and organs. [0003] Diabetic patients are more likely to develop eye diseases than non-diabetics, such as fundus hemangioma, fundus hemorrhage, cataract, vitreous opacity, macular degeneration, retinal detachment, etc., which can easily cause blindness and seriously affect the quality of life of patients. Cataracts...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61P3/10A61P27/02A61P27/12
CPCA61K31/216
Inventor 陈民利屠珏马全鑫杨钦钦戎亦骊陈小真
Owner CHIATAI QINGCHUNBAO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com